POLE and endometrial cancer: Determining which molecular subtype (POLE mut, MMRd, p53abn, and NSMP) is a key factor for choosing the appropriate adjuvant therapy [60].The detection of POLE mut or p53abn subtypes in the early stages of endometrial cancer is now a main criterion for 2023 staging.